WASHINGTON, DC--(Marketwired - Jul 11, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces Mr. Raymond C. Dabney, President, Chief Executive Officer, and Co-Founder of Cannabis Science, Inc. (OTC PINK: CBIS) has accepted an invitation to serve as a Co-Chair of this year's Ronald H. Brown African Affairs Series organized by the Constituency for Africa (CFA). The theme of this year's event, scheduled from September 12-17th in Washington, DC, is "Setting the US-Africa Agenda for the Next Administration."

As a Co-Chair, Mr. Dabney joins a distinguished group of leaders from the public and private sectors for CFA's annual event. In this capacity, Mr. Dabney will have the opportunity to discuss CBIS' initiatives in Sub-Saharan Africa with key American and African stakeholders. "Through my participation in this year's Ronald H. Brown African Affairs Series, CBIS will create additional visibility for our educational and drug development plans in Sub-Saharan Africa, and engage with relevant stakeholders as we actively follow-up on my visit to South Africa and Namibia in May of this year," said Mr. Dabney.

Key participants and sponsors for CFA's 2016 Ronald H. Brown African Affairs Series include His Excellency Hage Geingob, President of Namibia; Ambassador Andrew J. Young; Ambassador Jendayi E. Frazer; the Honorable Ronald V. Dellums, former U.S. Congressman and Mayor of Oakland, CA; Mr. Denis-Christel Sassou Nguesso, Founder and President of the Foundation Perspectives d'Avenir in the Republic of Congo; Congresswoman Karen Bass; Chevron; the Directorate of Technical Cooperation in Africa; His Imperial Majesty Ooni Adeyeye Enitan Babatunde Ogunwusi, Ojaja II, the Ooni of Ile Ife in Nigeria; and CBIS.

Over the past 25 years, CFA has established itself as one of the leading organizations committed to educating and mobilizing the U.S. public on matters pertaining to Africa and the African Diaspora. This year's Ronald H. Brown African Affairs Series will feature a series of caucuses around key issues, including Healthcare Infrastructure, Trade & Investment, Capacity Building, Democracy & Governance, Africa's Young Leaders, Nutrition Security, and Mobilizing the Diaspora. At the conclusion of these caucuses, CFA will convene a senior-level, Africa Policy Forum to analyze the findings of the caucus groups and develop formal recommendations that will be presented to both political parties for consideration.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information:

Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
Tel: 1-888-263-0832

Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder

Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Tel: 1-888-263-0832